MarketPeel
Insider Trading Intelligence
Pricing
…
MW

Milton H. Werner

IKT
PRESIDENT AND CEO · INHIBIKASE THERAPEUTICS, INC. · CIK 0001827621
FILING MIX · LIFETIME73%/27%
BUYS
24
SELLS
9
TOTAL VALUE
$244.0K
COMPANIES
1
ACTIVE SINCE
Dec 2020
HOLDINGS NOW
35,000
AVG SELL PX
$4.59
TRADE KIND
SHOWING 33 / 33
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Milton H. Werner, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+100.00%+7.95%+0.35%+7.60%+2.75%—
14d8+37.50%+4.85%-3.37%+8.21%-2.80%—
30d8+25.00%-3.30%-3.50%+0.20%-16.26%—
60d8+25.00%-6.83%-2.83%-4.00%-15.28%—
90d8+12.50%-25.36%-2.22%-23.14%-33.00%—
180d8+0.00%-46.03%-9.11%-36.92%-50.75%—
1y8+0.00%-51.79%-7.05%-44.74%-50.39%—
2y8+0.00%-82.24%+12.63%-94.86%-91.89%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IKT · 35,000 shares · as of Jan 21, 2025
01,333,8582,667,7174,001,5755,335,43320212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
FLOW · 24 buys / 9 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,834——20,834Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,643——3,643Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
3,643——0Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,667——16,667Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
35,000——0Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
16,667——0Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
45,000——0Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
20,834——0Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,000——35,000Jan 21, 2025Jan 22, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,059,744——4,059,744Jan 3, 2025Jan 7, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,315,056——5,315,056Jan 3, 2025Jan 7, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,207,671——2,207,671Jan 3, 2025Jan 7, 2025 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Apr 1, 2024Apr 3, 2024 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
210,000——210,000Mar 1, 2023Mar 3, 2023 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
5,000$0.80$4.0K5,335,433Aug 16, 2022Aug 16, 2022 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
5,000$0.98$4.9K5,330,433May 27, 2022May 31, 2022 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
10,000$0.60$6.0K5,325,433May 20, 2022May 23, 2022 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000——125,000Mar 7, 2022Mar 21, 2022 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000——125,000Mar 7, 2022Mar 9, 2022 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
21,853——0Jan 3, 2022Jan 4, 2022 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
21,853$2.02$44.1K5,315,433Jan 3, 2022Jan 4, 2022 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
400$1.93$77223,589Nov 17, 2021Nov 19, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
17,569$1.98$34.8K23,589Nov 17, 2021Nov 19, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
3,186$1.96$6.2K23,589Nov 17, 2021Nov 19, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
1,100$1.97$2.2K23,589Nov 17, 2021Nov 19, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
1,334$1.94$2.6K23,589Nov 17, 2021Nov 19, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
21,853$2.02$44.1K5,293,580Aug 17, 2021Aug 19, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
21,853——0Aug 17, 2021Aug 19, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
16,918$4.59$77.7K5,271,727May 14, 2021May 18, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
President and CEO
43,707$0.38$16.6K5,288,645May 14, 2021May 18, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
SALE
President and CEO
43,707——0May 14, 2021May 18, 2021 ↗View →
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Dec 22, 2020Dec 29, 2020 ↗View →
Other insiders · IKT
Loading peer insiders…
About this filer
CIK 0001827621
ROLE
President and CEO
PRIMARY
IKT
COMPANIES
1
ACTIVE SINCE
Dec 2020
MARKETPEEL · /INSIDER/0001827621DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback